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The severity of cystic ﬁbrosis (CF) pulmonary disease is not directly related to CFTR genotype but depends upon several parame-
ters, including neutrophil-dominated inﬂammation. Identiﬁcation of agents modulating inﬂammation constitutes a relevant goal.
Myeloperoxidase (MPO) is involved in both microbicidal and proinﬂammatory neutrophil activities. The aim of this study was to
evaluate whether the −463GA MPO promoter polymorphism is linked to clinical severity of CF-associated pulmonary inﬂamma-
tion. This polymorphism signiﬁcantly aﬀects the level of MPO gene expression in leukocytes and the G allele is more expressing
than the A allele. We show that MPO genotype signiﬁcantly inﬂuences the severity of pulmonary disease in early stages, prior to
thedevelopmentofchroniclunginfections,withGGgenotypebeingassociatedwithmoresevereCFdisease.Ourﬁndingsindicate
that the level of MPO gene expression inﬂuences the CF pathogenesis, presumably reﬂecting cellular damage by MPO-generated
oxidants or other activity of MPO in airway inﬂammation.
Copyright © 2006 Wanda F. Reynolds et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Cystic ﬁbrosis (CF) is a lethal autosomal recessive disorder
which is caused by mutation of the cystic ﬁbrosis transmem-
brane regulator (CFTR) gene [1]. Although CF is a multi-
organ disease, most of the morbidity and the mortality are
duetoprogressivepulmonarydiseasewithlungparenchymal
destruction and chronic pulmonary bacterial colonization
[2, 3]. There is a hypersecretion and a massive inﬂux of neu-
trophils within the airways which mediate deleterious eﬀects
[4, 5]. Moreover, the intensity of the airway inﬂammation is
directly correlated with the clinical status as evidenced by a
close correlation between respiratory scores and neutrophil-
derived proteinases [6]. The airway inﬂammation typical of
CF relies thus on the paradox of misdirected neutrophil mi-
crobicidalactivityresultinginanexacerbationofneutrophil-
mediated tissue damage and a concomitant failure in the
antimicrobial system, since CF patients can become chron-
ically infected with Pseudomonas aeruginosa (Pa e r u g i n o s a )
[7, 8]. Activation of the neutrophil results in the oxidative
burst which occurs at the level of NADPH oxidase leading to
the generation of superoxide anion which can dismutate into
hydrogen peroxide (H2O2)[ 9, 10]. Myeloperoxidase (MPO),
an enzyme contained in azurophil granules, catalyzes the
H2O2-dependent oxidation of chloride (Cl−), which yields
hypochlorous acid (HOCl) [11]. HOCl is a potent microbi-
cidal agent and a toxic chlorinating oxidant. MPO released
from activated neutrophils can also damage bystander cells
at inﬂammatory sites. Airway secretions from CF patients
containedhighconcentrationsofactiveMPO[12]thatcould
catalyze protein tyrosine oxidation and produce high lev-
els of dityrosine, 3-chlorotyrosine, and 3-nitrotyrosine [13].
Levels of MPO were correlated with poor clinical conditions
and sputum production [14], thus demonstrating that extra-
cellular MPO could contribute to hypersecretion, bronchial
injury, and respiratory failure in CF. MPO could be a criti-
cal parameter in the modulation of inﬂammation and/or in-
fection because MPO is involved in both microbicidal and
proinﬂammatory activities of neutrophils.2 Mediators of Inﬂammation
When we have studied puriﬁed circulating neutrophils in
CF, we provided evidence of a signiﬁcant increase in MPO-
dependent oxidant formation in both CF children and their
parents as compared to controls, whereas NADPH activity
was similar to that of controls. This increased intracellular
MPO activity observed in CF homozygotes and heterozy-
goteswasobservedatthebasallevelaswellasfollowingPMA
or opsonized zymosan stimulation [15]. The fact that this
increase was observed in the parents of CF children, which
are heterozygous for CFTR mutation but are free of clini-
cal symptoms, led us to the conclusion that the disturbance
in MPO activity observed in CF was constitutive, indepen-
dent from infection. These prior studies demonstrated that
increased MPO activity could potentiate inﬂammation in CF
patients.
In the present study, we asked whether a functional MPO
promoter polymorphism inﬂuenced their clinical outcome.
The −463G/A polymorphism is linked to the diﬀerences
in MPO expression levels [16, 17]: the −463G/A promoter
polymorphism signiﬁcantly aﬀects the level of MPO gene
expression in bone marrow precursors and in descendant
leukocytes. The G allele is more expressing than the A al-
lele. This polymorphism is linked to incidence or sever-
ity of inﬂammatory diseases including atherosclerosis [18,
19], Alzheimer’s [20–22],MPO-ANCA vasculitis [23], HCV-
induced ﬁbrosis [23], multiple sclerosis [24], periodontal
disease [25], lung cancer [26, 27], and myeloid leukemia
[24]. This polymorphism is in an Alu element, within a clus-
ter of four hexamer half sites recognized by various nuclear
receptors [17] and termed an Alu receptor response element
(AluRRE). These hexamers are organized as direct repeats
with spacing of two-four-two base pair. The −463A is in
hexamer 1 within an estrogen receptor binding site [16],
while −463G promotes binding by SP1 transcription factor
[17]. The hexamer 3/4 pair is recognized by retinoic acid re-
ceptor and PPARγ as heterodimers with retinoid X recep-
tor (RAR-RXR), while the middle DR-4 pair (hexamers 2/3)
is recognized by thyroid hormone receptor (TR-RXR). The
−463GG genotype has been linked to higher MPO mRNA
and protein expression than GA/AA genotypes in primary
myeloid leukemia cells and monocyte-macrophages [28],
while in transfection assays, the −463G promoter element
supported higher expression of a reporter gene than −463A
[17]. In a recent study performed in human monocyte-
derived macrophages, we have provided evidence that MPO
gene expression was downregulated as iNOS (inductible ni-
tric oxide synthase) was upregulated, thus suggesting a po-
tential connection between these two enzymes [29]. Because
NO has physiological importance in airways, a diﬀerence in
MPO expression levels could be relevant in the pulmonary
disease in CF.
MPO could be considered a candidate for potential ge-
netic modiﬁers of disease severity in patients with CF not
necessarily related to infection. Indeed, MPO can also play
a signiﬁcant proinﬂammatory role in the absence of in-
fection, in atherogenesis, or in neurodegenerative diseases.
The mechanisms leading to neutrophil-dominated inﬂam-
mation in CF patients as well as the relationships with CFTR
mutations remain largely unknown. The course of lung dis-
ease in patients with CF varies considerably, even among pa-
tients with the same CFTR who are receiving standardized
care [7]. This variation is largely unexplained. So far, sev-
eral genes implicated in innate immunity and in the control
of inﬂammation have been studied as potential modiﬁers of
CF [30]. Among them, mannose-binding lectin [31], alpha-
antitrypsin [32], glutathione S-transferase, TNF-alpha, IL-1
beta, and IL-1 RA have already been studied [33]. Interest-
ingly, a possible link between the NOS1 gene locus and the
rate of decline in lung function in CF patients has been de-
scribed[34].Sofar,thereisnodataavailableontheinﬂuence
of MPO genotype on the clinical course of CF.
In the present study, we investigate the inﬂuence of the
MPO promoter polymorphism on the clinical severity of CF
disease. Our results clearly demonstrate that MPO genotype
inﬂuences the severity of the lung disease in CF patients in
the absence of infection, with the GG genotype associated
with more severe CF disease. In infected CF patients, the GG
genotype was associated with an increase in the circulating
neutrophil inﬂammatory state.
METHODS
Studypopulation
Eighty eight patients with CF including 45 males and 43 fe-
males (mean age: 17.8 ± 0.74 years) were recruited for the
study. Informed consent was obtained from patients or their
parents and the clinical research was conducted according to
the guidelines of the French Institut National de la Sant´ ee t
delaRechercheScientiﬁque(INSERM)andtheFrenchethics
committee. CF was diagnosed according to the standard cri-
teria including a sweat chloride test. Patient’s clinical status
was evaluated in CF patients by the Shwachman-Kulczycki
scoring system [35] which includes nutritional criteria, the
highest value being 100. The pulmonary function was as-
sessed by spirometry and expressed as percent-predicted
FEV1 (forced expiratory volume in one second) and FVC
(forced vital capacity) normalized for age and height [36].
The severity of lung disease was evaluated according to the
chest radiograph and the number of radiologic lesions (ob-
structivelesionsandsegmentalordiﬀusebronchiectasiswere
counted).
The lung infection was determined in 77 CF patients on
the basis of bacteriological analysis of sputum, which was
collected according to the methodology previously described
[36]. On the basis of sputum bacterial qualitative and quan-
titative analysis, bronchial infection was deﬁned as bacterial
counts ≥ 108 colony forming units (CFU)/l in at least 3 cul-
tures at one-month interval, and CF patients were stratiﬁed
into three groups.
A ﬁrst group designated “uninfected CF children” in-
cluded 32 children without history or evidence of Pa e r u g -
inosa infection. At the time of testing, sputum cultures were
all negative and all children were stable and clinically well.
The second group designated “infected CF children” in-
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aureus (S aureus) (n = 8) or chronically colonized with P
aeruginosa (n = 37).
AnalysisofCFTRmutationsbyPCR
anddirectsequencing
Genotyping of CF patients was performed as previously de-
scribed [37–39]. In the CF population tested, 73% carried
the delta F508 mutation with 50% being delta F508 homozy-
gote, 23% being delta F508 heterozygote with an unknown
mutation, and 27% having mutations other than delta F508
at both alleles as previously described [36].
DeterminationofMPOgenotypebyallelic
discriminationassay
DNA was isolated from leukocytes by proteinase K diges-
tion followed by phenol extraction and ethanol precipita-
tion. DNA (100ng) was used in the ABI 7900 allelic dis-
crimination assay using dual ﬂuorophore probes which dis-
criminate between alleles based on the single base mis-
match. Primers and probes, designed using the Primer Ex-
press 2.0 software (ABI), are as follows: forward primer, 5 -
AATCTTGGGCTGGTAGTGCTAAA-3 ; reverse primer, 5 -
GCCAGGCTGGTCTTGAACTC-3 ; −463A speciﬁc probe,
5 -FAM TCCACCTGCCTCAG MGB; and −463G speciﬁc
probe,5 -VICTCCACCCGCCTCAMGB.Probesarelabeled
at the 5  end with the ﬂuorophores FAM or VIC and are sta-
bilized by a minor groove binding moiety (MGB). Endpoint
allelic speciﬁc ﬂuorescence was measured on the ABI prism
7900 using the Sequence Detection Systems 2.0 software for
allelic discrimination.
Statisticalanalysis
Statistical analysis was performed using the Statview soft-
ware. Comparisons were made by analysis of variance
(ANOVA) or unpaired Student t test. Data are expressed as
mean ± standard error of the mean (SEM).
RESULTS
FrequenciesofMPOgenotypeinCFpatients
ascomparedtocontrolpopulation
We determine the MPO genotype for 79 CF children. As
shown in Table 1, there is no diﬀerence in the percentages
of the GG, GA, or AA genotypes in the CF population as
compared to the frequencies within normal European popu-
lations [16, 26, 40]. When the cases were stratiﬁed by gender,
there was no statistically signiﬁcant diﬀerence.
InﬂuenceofMPOgenotypeonclinical
parametersofCFdisease
Since clinical conditions in CF patients are greatly inﬂuenced
by recurrent infections, it was relevant to evaluate the inﬂu-
ence of MPO genotype within a homogeneous group of CF
Table 1: Frequencies of MPO genotype in the population of CF
children.
CF patients (n = 79) Males (n = 42) Females (n = 37)
GG 47/79 = 59.49% 28/42 = 66.67% 21/37 = 56.76%
GA 30/79 = 37.97% 13/42 = 30.95% 15/37 = 40.54%
AA 2/79 = 2.53% 1/42 = 2.4% 1/37 = 2.7%
patientsaccordingtoinfectious/inﬂammatorycriteria.When
comparing the respiratory scores between the ﬁrst group of
noninfected CF patients, the second group of Sa u r e u s ,a n d
the third group of Pa e ru gi n o s a -infected patients, it appeared
that the FEV was signiﬁcantly diﬀerent in the noninfected
(n = 32, 79.3±3.9) versus the group of Sa u r e u s -infected CF
patients (n = 8, 56.75 ± 5.2, P = .009) and versus the group
of Pa e r u g i n o s a -infected CF patients (n = 37, 60.55 ± 4.1,
P = .002). In contrast, there was no diﬀerence in the FEV in
the group of Sa u r e u s -a sc o m p a r e dt oPa e r u g i n o s a -infected
CF patients (P = .674). As a result, for further analysis, only
two homogeneous groups, in terms of severity of CF disease,
will be considered: noninfected CF patients and infected CF
patients, mainly composed of Pa e r u g i n o s achronically in-
fected CF patients. As shown in Table 2, the group of in-
fected CF children clearly diﬀered from the groups of nonin-
fected CF children on the basis of respiratory scores (FEV or
FVC) or infectious score measured as the number of antibio-
therapies during the past year. Although not statistically sig-
niﬁcant, there was a clear diﬀerence in the Shwachman and
in the radiographic scores between noninfected and infected
CF patients; the noninfected CF patients having more severe
Shwachman and radio scores. Of note, the mean age of the
noninfected CF patients was signiﬁcantly lower than the age
in the infected CF patients. This could be expected since in-
fection occurs in the course of the disease and thus aﬀects
older patients.
Within each group, either the noninfected or the infected
CF patients, we evaluated the inﬂuence of MPO genotype.
As shown in Figure 1(a), in the group of noninfected CF pa-
tients, there is signiﬁcantly lower FEV in CF patients with
GG than GA genotype (73.5±5.6v e r s u s9 5 .7±8.2, P = .03).
Likewise,FVCwassigniﬁcantlylowerinCFpatientswithGG
genotype than with GA (80.8±4.0v e r s u s9 9 .7±6.7, P = .01,
resp). As expected, there was more lesions seen on chest ra-
diographyinGGthaninGA(23.6±8.6v ersus5.5±1.5,resp).
Shwachman scores were decreased in the group of GG geno-
type as compared to GA (64.3 ± 9.1v e r s u s8 7 .8 ± 3.4, resp).
The number of antibiotherapies was higher in GG than in
GA (3.5 ± 1.2v e r s u s2 .4 ± 0.8, resp). Of note, the mean age
of the CF patients was not diﬀerent between the groups of
GG and GA providing evidence that there was no artifact of
older patients inGG groupexplaining their more severeclin-
ical expression (Table 3).
In contrast, in the group of infected CF patients, there
was no signiﬁcant diﬀerence in clinical parameters between
GG and GA genotypes evaluated either by respiratory scores
(FEV or FVC) (Figure 1(b)) or by radiography scores. There
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Table 2: Clinical characteristics of CF patients stratiﬁed with their infectious status. A total of 77 CF children were studied and two groups
were made up according to the infectious status of the CF patients. The data are the mean ± SEM. The radio score indicates the number of
lesions observed on the chest radiography. The ATB refers to the number of antibiotherapy treatment during the preceding year.
Age (y) FEV % FVC % Shwachman Radio ATB
Noninfected CF n = 32 15.8 ± 0.98 0 .9 ±3.98 5 .8 ±2.97 5 .8 ±4.38 .2 ±1.32 .7 ±0.5
Infected CF n = 45 18.6 ± 0.85 9 .3 ±3.47 2 .5 ±2.96 6 .9 ±2.92 0 .2 ±3.77 .0 ±0.7
P = .02 P<. 0001 P = .002 P = .08 P = .018 P<. 0001
genotype(61.0±5.4v e r s us59.6±4.7, resp).Likewise,nodif-
ference was observed in FVC with GG or with GA genotype
(73.1 ± 4.6v e r s u s7 4 .2 ± 4.3, resp). It could be noted, how-
ever, that the Shwachman score was higher in the group of
GA than in the group of GG phenotype, butthis increase was
not statistically signiﬁcant. With regard to the number of an-
tibiotherapies in the preceding year, there was no signiﬁcant
diﬀerence. Interestingly, this lack of inﬂuence of MPO geno-
type on clinical parameters was observed separately both
in the subgroup of CF children chronically infected with P
aeruginosa and in the subgroup of CF children infected with
Sa u r e u s(data are not shown).
Taking together, our data strongly suggest that the MPO
genotypeinﬂuencestheclinicalcourseofthediseasewithless
severity for the GA allele versus the GG allele in CF patients,
intheabsenceofinfection.Incontrast,asfarasthereisanin-
fection and especially a chronic Pa e r u gi n o s ainfection, MPO
genotypeisnotasdiscriminative,andtheGAgenotypeisnot
associated with better clinical status.
Inﬂuenceofgender
Since a number of studies have shown that the inﬂuence of
MPO genotype could be gender-speciﬁc [20, 23], we com-
pared the inﬂuence of MPO genotype in CF females and CF
males. No inﬂuence of gender was observed. We conﬁrmed
that, in the absence of infection, in either CF females or CF
males, the GG genotype was associated with a more severe
lungdiseaseandworseclinicalconditions.Inthegroupofin-
fectedCFpatients,therewasnosigniﬁcantinﬂuenceofMPO
genotype in CF females or males, thus corroborating the re-
sults found in the mixed population.
InﬂuenceoftheCFTRmutation
CF patients were stratiﬁed into two groups according to their
CFTR mutation, either homozygotes ΔF508/DF508 or het-
erozygotes ΔF508/others. The group of patients having the
CFTR genotype corresponding to other/other was so small
that we could not perform analysis. Within the group of
ΔF508/DF508 or within the group of ΔF508/others, we con-
ﬁrmed what we have found for the whole population, which
is that the GA phenotype was associated with better clinical
parametersascomparedwithGG,intheabsenceofinfection.
In infected CF patients, there was no eﬀect of MPO genotype
whatever the CFTR genotype. These results concerning the
inﬂuence of CFTR mutation on the clinical severity of the
disease are not surprising since the CFTR genotype is not re-
lated to the inﬂammatory status of the patient, and it is now
well documented that there is no correlation between CFTR
genotype and the evolution of lung disease.
DISCUSSION
Our present ﬁndings establish for the ﬁrst time that the GG
MPOgenotypeisassociatedwithmoresevereclinicalexpres-
sion of CF disease in the absence of infection. The G allele
is the higher expressing allele, and the GG genotype is most
oftenassociated withworsedisease.Thus,theﬁndingsin this
paper linking GG genotype to worse outcome in CF is con-
sistent with most prior studies.
In CF patients, the association of the higher expressing
GG genotype with more severe disease in the absence of in-
fection implies that MPO enzyme contributes to the inﬂam-
matorystatusinnoninfectedpatients.Ourdatasuggestasig-
niﬁcant proinﬂammatory role for MPO in the early phase
of CF, in the absence of infection. Several hypotheses can
be made to explain the inﬂuence of MPO in airways in the
absence of infection and the potential mechanisms resulting
in the presence of MPO within airways. Firstly, noninfected
CF patients means that these patients are non-chronically
infected by Pa e r u g i n o s aor Sa u r e u sand they do not have
any detectable infection demonstrated by negative bacterial
analysis of the sputum at the time of the clinical analysis.
In our study, we diﬀerentiated between noninfected CF pa-
tients and chronically infected patients because their clini-
cal status were signiﬁcantly diﬀerent. However, our classiﬁ-
cation does not rule out some subclinical infection, which
could explain the presence of some neutrophils within the
lung. Secondly, it has been described that there is a “con-
stitutive” inﬂammatory process in CF epithelial cells with a
basal activation of the transcription factor NF-kB in the ab-
sence of infection [41]. It has been reported that epithelial
cells from CF patients have the ability to secrete more IL-8,
which is a potent chemoattractant for neutrophils [42, 43].
It can be hypothesized that inﬂammatory cytokines could
attract neutrophils and/or upregulate MPO in macrophage
in the absence of infection. The inhibitory role of MPO on
the regulation of NOS might also explain the better clinical
conditions associated with the GA genotype (producing less
MPO).Indeed,epithelium-derivedNOreducedPaeruginosa
adherence and enfance killing of bacteria [44], and NOS ex-
pression decreased in CF as airway inﬂammation increases
[45]. A combined study of NOS and MPO gene expressionWanda F. Reynolds et al 5
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Figure 1: Inﬂuence of MPO genotype on respiratory scores in CF
patients. FEV % (on the left) and FVC % (on the right) were mea-
sured in (a) 21 noninfected CF patients either with (n = 14) for
the GG or (n = 7) for the GA genotype and (b) 37 chronically in-
fected CF patients with (n = 22) for the GG or with (n = 15) for
the GA genotype. The data are the mean ± SEM. Diﬀerences were
statistically signiﬁcant (∗P = .03 and ∗∗P<. 001).
and polymorphisms might be relevant to CF and would help
to understand the variability of the clinical expression of the
pulmonary disease.
In chronically infected CF patients, the GA genotype is
not as beneﬁcial as it is in noninfected patients. The ob-
servation that GG genotype is not associated with greater
resistance to Pa e r u g i n o s aor fewer infection per year sug-
gests that MPO does not play a critical role in the antimi-
crobial systems of CF neutrophils. In this situation, many
neutrophils are recruited within airways and these fail to kill
the bacteria (Sa u r e u sor Pa e r u g i n o s a ). One would expect
that CF patients having more MPO (GG genotype) would be
more eﬃcient in killing bacteria and thus would have less se-
vere pulmonary disease. We do not see any diﬀerence in the
severity of the pulmonary disease between GG and GA geno-
types who are chronically infected.
Our study thus emphasized that MPO contributes sig-
niﬁcantly to the proinﬂammatory eﬀects of PMN. In the ab-
senceofinfection,genotypeGGmaybemoredeleteriousdue
to exacerbation of the inﬂammatory process and production
of more oxidants which damage the airways and epithelium.
When chronic colonization with Pa e r u g i n o s aoccurs, the
increased production of chlorinated oxidants could be an
advantage, counterbalancing the negative impact of oxida-
tive damage to the epithelium, such that GG genotype may
have both positive and negative impact; thus the diﬀerence
between GG and GA is less noticeable. Moreover, additional
physiopathological mechanisms are involved in the destruc-
tion of airways depending on the bacteria, thus masking
the clear-cut inﬂuence of MPO genotype on the clinical
expression of CF disease that we have observed in nonin-
fected patients. Another interesting aspect of our results is
the fact that MPO activity could result in the formation of
inﬂammatory mediators by oxidizing mucus components, as
it has previously been reported for plasma components in
hemodialyzedpatients[46].Indeed,ithasbeenreportedthat
neutrophils components, especially elastase, can stimulate
mucus secretion in airways [47] via an oxidant-dependent
mechanisms. It would be pertinent to study whether MPO-
modiﬁed mucins could have some inﬂammatory activities.
This could ﬁt with the data that MPO levels in neutrophils
were correlated with sputum production [14], thus suggest-
ingthatMPOcouldbelinkedwithCFmucushypersecretion.
Several studies on the mechanisms of inﬂammation in
CF have now shown that a genetic disease like CF is not as
simple as originally envisioned. The cloning of the CFTR
was a major milestone in understanding the molecular basis
of CF, but dissecting the pathogenesis of CF has proven far
more complicated. The challenge remains to select appropri-
a t eg e n ep o l ym o r p h i s m sa n di n v e s t i g a t et h e i re ﬀects in order
to achieve a more complete understanding of the pathogen-
esis of a disease as complex as CF. The identiﬁcation of a col-
lection of modifying genotypes could lead to a more reﬁned
understanding of speciﬁc disease. In a study focused on po-
tential genetic modiﬁers of disease severity in chronic granu-
lomatous disease (CGD) patients, genotype of MPO and Fc
gamma RIII were found to be strongly associated with an in-
creased risk for gastrointestinal complications. There were,
however, no data on MPO activity in PMN from CGD pa-
tients or addressing the possibility that MPO genotype could
modulate levels of MPO activity [48].
Understanding the role of modifying genes has consider-
able potential for determining risk proﬁle that might impact
therapeutic decisions. By subclassifying disease, according6 Mediators of Inﬂammation
Table 3: Inﬂuence of MPO genotype on clinical parameters of CF disease. The −463G/A MPO polymorphism was determined in 58 CF
patients as described in the “methods.” The inﬂuence of the polymorphism of MPO promoter was studied either in (a) noninfected or
in (b) chronically infected CF children. The data are the mean ± SEM. The radio score indicates the number of lesions seen on the chest
radiography. The ATB means the number of antibiotherapy treatment during the preceding year. NS: P>. 05.
(a)
Age (y) Shwachman Radio ATB
GG (n = 14) 18.6 ±0.96 4 .3 ±9.12 3 .6 ±8.63 .5 ±1.2
GA (n = 7) 18.0 ±1.38 7 .8 ±3.45 .5 ±1.52 .4 ±0.8
NS P = .08 NS NS
(b)
Age (y) Shwachman Radio ATB
GG (n = 22) 18.7 ±0.86 3 .3 ±4.81 9 .2 ±4.56 .9 ±1.0
GA (n = 15) 17.7 ±2.17 1 .1 ±3.81 2 .1 ±1.47 .1 ±1.5
—N SN S N S
to secondary genetic risk factors, therapy could be adapted
to individuals need. Indeed, the current study strongly sug-
gestthatpharmacologicalmodulation of MPOactivitycould
havediﬀerenteﬀectsdependingonMPOgenotypeandMPO
inhibitors may have a more beneﬁcial eﬀect in CF patients
having GG phenotype.
In summary, our hypothesis is that, in CF, the MPO
promoter polymorphism −463G/A, which inﬂuences the
amount of neutrophil MPO, could modulate inﬂammatory
and/or infection processes, thereby modulating the severity
of the pulmonary disease. MPO-HOCl is known to oxidize a
variety of biological molecules, and can have signiﬁcant im-
pact at inﬂammatory sites, independent of infection. This is
likely to explain the observed diﬀerence between the MPO
genotypes in severity of pulmonary disease in noninfected
CF patients.
ACKNOWLEDGMENTS
The authors wish to thank Dr Pierre-Regis Burgel from
Cochin Hospital for stimulating discussions, Dr Anh Thu
Nguyen for data managing, and the excellent technical assis-
tance of Nadya Mothu. This work was supported by the As-
sociation ABCF protein and Vaincre la Mucoviscidose (VWS
and BDL) and by a grant to WF Reynold from the National
Institutes of Health (RO1 AG17879). We thank the ﬁnan-
cial support of Baxter and AMGEN. This work has been pre-
sentedasanoralcommunicationatthe28thEuropeanCystic
Fibrosis Conference, Hersonissos, Crete, Greece, 22–25 June
2005.
REFERENCES
[1] Cheng SH, Gregory RJ, Marshall J, et al. Defective intracellular
transport and processing of CFTR is the molecular basis of
most cystic ﬁbrosis. Cell. 1990;63(4):827–834.
[2] DavisPB.Cysticﬁbrosis.PediatricsinReview.2001;22(8):257–
264.
[3] Chmiel JF, Berger M, Konstan MW. The role of inﬂammation
in the pathophysiology of CF lung disease. Clinical Reviews in
Allergy & Immunology. 2002;23(1):5–27.
[4] Birrer P, McElvaney NG, Rudeberg A, et al. Protease-
antiprotease imbalance in the lungs of children with cys-
tic ﬁbrosis. American Journal of Respiratory and Critical Care
Medicine. 1994;150(1):207–213.
[5] Witko-Sarsat V, Rieu P, Descamps-Latscha B, Lesavre P,
Halbwachs-MecarelliL.Neutrophils:molecules,functionsand
pathophysiological aspects. Laboratory Investigation. 2000;80
(5):617–653.
[6] Witko-Sarsat V, Halbwachs-Mecarelli L, Schuster A, et al. Pro-
teinase 3, a potent secretagogue in airways, is present in cys-
tic ﬁbrosis sputum. American Journal of Respiratory Cell and
Molecular Biology. 1999;20(4):729–736.
[7] Ramsey BW. Management of pulmonary disease in patients
with cystic ﬁbrosis. The New England Journal of Medicine.
1996;335(3):179–188.
[8] Pier GB. Role of the cystic ﬁbrosis transmembrane conduc-
tance regulator in innate immunity to Pseudomonas aerugi-
nosainfections.ProceedingsoftheNationalAcademyofSciences
of the United States of America. 2000;97(16):8822–8828.
[9] Babior BM. NADPH oxidase: an update. Blood. 1999;93(5):
1464–1476.
[10] Clark RA. Activation of the neutrophil respiratory burst
oxidase. The Journal of Infectious Diseases. 1999;179(suppl
2):S309–S317.
[11] Klebanoﬀ SJ. Myeloperoxidase. Proceedings of the Association
of American Physicians. 1999;111(5):383–389.
[12] Witko-Sarsat V, Delacourt C, Rabier D, Bardet J, Nguyen AT,
Descamps-Latscha B. Neutrophil-derived long-lived oxidants
in cystic ﬁbrosis sputum. American Journal of Respiratory and
Critical Care Medicine. 1995;152(6 pt 1):1910–1916.
[13] Van Der Vliet A, Nguyen MN, Shigenaga MK, Eiserich JP,
Marelich GP, Cross CE. Myeloperoxidase and protein oxida-
tionincysticﬁbrosis.AmericanJournalofPhysiology.LungCel-
lular and Molecular Physiology. 2000;279(3):L537–L546.
[14] Garner HP, Phillips JR, Herron JG, Severson SJ, Milla CE,
Regelmann WE. Peroxidase activity within circulating neu-
trophils correlates with pulmonary phenotype in cystic ﬁbro-
sis. Journal of Laboratory and Clinical Medicine. 2004;144(3):
127–133.Wanda F. Reynolds et al 7
[15] Witko-Sarsat V, Allen RC, Paulais M, et al. Disturbed mye-
loperoxidase-dependent activity of neutrophils in cystic ﬁ-
brosis homozygotes and heterozygotes, and its correction
by amiloride. The Journal of Immunology. 1996;157(6):2728–
2735.
[16] Piedraﬁta FJ, Molander RB, Vansant G, Orlova EA, Pfahl M,
Reynolds WF. An Alu element in the myeloperoxidase pro-
moter contains a composite SP1-thyroid hormone-retinoic
acid response element. The Journal of Biological Chemistry.
1996;271(24):14412–14420.
[17] Vansant G, Reynolds WF. The consensus sequence of a major
Alu subfamily contains a functional retinoic acid response el-
ement. Proceedings of the National Academy of Sciences of the
United States of America. 1995;92(18):8229–8233.
[18] Nikpoor B, Turecki G, Fournier C, Th´ eroux P, Rouleau GA. A
functional myeloperoxidase polymorphic variant is associated
with coronary artery disease in French-Canadians. American
Heart Journal. 2001;142(2):336–339.
[19] Pecoits-Filho R, Stenvinkel P, Marchlewska A, et al. A func-
tional variant of the myeloperoxidase gene is associated with
cardiovascular disease in end-stage renal disease patients. Kid-
ney International. 2003;63(suppl 84):S172–S176.
[20] Reynolds WF, Rhees J, Maciejewski D, et al. Myeloperoxi-
dase polymorphism is associated with gender speciﬁc risk for
Alzheimer’s disease. Experimental Neurology. 1999;155(1):31–
41.
[21] Crawford FC, Freeman MJ, Schinka JA, et al. Association be-
tween Alzheimer’s disease and a functional polymorphism in
the Myeloperoxidase gene. Experimental Neurology. 2001;167
(2):456–459.
[22] Leininger-Muller B, Hoy A, Herbeth B, et al. Myeloperoxidase
G-463ApolymorphismandAlzheimer’sdiseaseintheApoEu-
rope study. Neuroscience Letters. 2003;349(2):95–98.
[23] Reynolds WF, Patel K, Pianko S, Blatt LM, Nicholas JJ,
McHutchison JG. A genotypic association implicates myelo-
peroxidase in the progression of hepatic ﬁbrosis in chronic
hepatitis C virus infection. Genes & Immunity. 2002;3(6):345–
349.
[24] Nagra RM, Becher B, Tourtellotte WW, et al. Immunohisto-
chemical and genetic evidence of myeloperoxidase involve-
ment in multiple sclerosis. Journal of Neuroimmunology. 1997;
78(1-2):97–107.
[25] Meisel P, Krause T, Cascorbi I, et al. Gender and smoking-
related risk reduction of periodontal disease with variant
myeloperoxidase alleles. Genes & Immunity. 2002;3(2):102–
106.
[26] London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic
polymorphism and lung cancer risk. Cancer Research. 1997;57
(22):5001–5003.
[27] Schabath MB, Spitz MR, Hong WK, et al. A myeloperoxidase
polymorphism associated with reduced risk of lung cancer.
Lung Cancer. 2002;37(1):35–40.
[28] Kumar AP, Piedraﬁta FJ, Reynolds WF. Peroxisome
proliferator-activated receptor γ ligands regulate myeloperox-
idase expression in macrophages by an estrogen-dependent
mechanism involving the -463GA promoter polymorphism.
The Journal of Biological Chemistry. 2004;279(9):8300–8315.
[29] KumarAP,RyanC,CordyV,ReynoldsWF.Induciblenitricox-
idesynthaseexpressionisinhibitedbymyeloperoxidase.Nitric
Oxide. 2005;13(1):42–53.
[30] Chanock SJ, Foster CB. SNPing away at innate immunity. The
Journal of Clinical Investigation. 1999;104(4):369–370.
[31] Garred P, Pressler T, Madsen HO, et al. Association of
mannose-binding lectin gene heterogeneity with severity of
lung disease and survival in cystic ﬁbrosis. The Journal of Clin-
ical Investigation. 1999;104(4):431–437.
[32] Henry MT, Cave S, Rendall J, et al. An alpha1-antitrypsin en-
hancerpolymorphismisageneticmodiﬁerofpulmonaryout-
come in cystic ﬁbrosis. European Journal of Human Genetics.
2001;9(4):273–278.
[33] Acton JD, Wilmott RW. Phenotype of CF and the eﬀects of
possible modiﬁer genes. Paediatric RespiratoryReviews.2001;2
(4):332–339.
[34] Texereau J, Marullo S, Hubert D, et al. Nitric oxide synthase
1 as a potential modiﬁer gene of decline in lung function in
patients with cystic ﬁbrosis. Thorax. 2004;59(2):156–158.
[35] ShwachmanH,kulczyckiLL.Long-termstudyofonehundred
ﬁve patients with cystic ﬁbrosis; studies made over a ﬁve- to
fourteen-year period. A.M.A. Journal of Diseases of Children.
1958;96(1):6–15.
[36] Witko-SarsatV,Halbwachs-Mecarelli L,Sermet-GaudelusI,et
al. Priming of blood neutrophils in children with cystic ﬁbro-
sis: correlation between functional and phenotypic expression
of opsonin receptors before and after platelet-activating factor
priming. The Journal of Infectious Diseases. 1999;179(1):151–
162.
[37] Fanen P, Ghanem N, Vidaud M, et al. Molecular characteriza-
tion of cystic ﬁbrosis: 16 Novel mutations identiﬁed by anal-
ysis of the whole cystic ﬁbrosis conductance transmembrane
regulator (CFTR) coding regions and splice site junctions. Ge-
nomics. 1992;13(3):770–776.
[38] Audrezet MP, Mercier B, Guillermit H, et al. Identiﬁcation of
12 novel mutations in the CFTR gene. Human Molecular Ge-
netics. 1993;2(1):51–54.
[39] Highsmith WE, Burch LH, Zhou Z, et al. A novel mutation
in the cystic ﬁbrosis gene in patients with pulmonary disease
but normal sweat chloride concentrations. The New England
Journal of Medicine. 1994;331(15):974–980.
[40] Reynolds WF, Hiltunen M, Pirskanen M, et al. MPO and
APOEε4 polymorphisms interact to increase risk for AD in
Finnish males. Neurology. 2000;55(9):1284–1290.
[41] Blackwell TS, Stecenko AA, Christman JW. Dysregulated NF-
κB activation in cystic ﬁbrosis: evidence for a primary inﬂam-
matory disorder. American Journal of Physiology. Lung Cellular
and Molecular Physiology. 2001;281(1):L69–L70.
[42] Tabary O, Escotte S, Couetil JP, et al. High susceptibility
for cystic ﬁbrosis human airway gland cells to produce IL-8
through the I κ B kinase α pathway in response to extracellular
NaCl content. The Journal of Immunology. 2000;164(6):3377–
3384.
[43] Joseph T, Look D, Ferkol T. NF-κB activation and sustained
IL-8 gene expression in primary cultures of cystic ﬁbrosis air-
way epithelial cells stimulated with Pseudomonas aeruginosa.
American Journal of Physiology. Lung Cellular and Molecular
Physiology. 2005;288(3):L471–L479.
[44] Darling KEA, Evans TJ. Eﬀects of nitric oxide on Pseudomonas
aeruginosa infection of epithelial cells from a human respira-
tory cell line derived from a patient with cystic ﬁbrosis. Infec-
tion and Immunity. 2003;71(5):2341–2349.
[45] Wooldridge JL, Deutsch GH, Sontag MK, et al. NO path-
way in CF and non-CF children. Pediatric Pulmonology.
2004;37(4):338–350.
[46] Witko-Sarsat V, Friedlander M, Nguyen Khoa T, et al. Ad-
vanced oxidation protein products as novel mediators of in-
ﬂammation and monocyte activation in chronic renal failure.
The Journal of Immunology. 1998;161(5):2524–2532.8 Mediators of Inﬂammation
[47] Takeyama K, Dabbagh K, Jeong Shim J, Dao-Pick T, Ueki IF,
Nadel JA. Oxidative stress causes mucin synthesis via trans-
activation of epidermal growth factor receptor: role of neu-
trophils. The Journal of Immunology. 2000;164(3):1546–1552.
[48] Foster CB, Lehrnbecher T, Mol F, et al. Host defense molecule
polymorphismsinﬂuencetheriskforimmune-mediatedcom-
plications in chronic granulomatous disease. The Journal of
Clinical Investigation. 1998;102(12):2146–2155.